Publication Date: June 2011
Top Reasons to Buy this Pharmaceutical Business Development Report
Build a Top-Notch Pharmaceutical Business Development and Licensing Team: Explore models of pharmaceutical business development and licensing team structure that bolster communication and streamline reporting relationships. Use detailed benchmarks to discover when other pharma and biotech companies pursue deals — and ensure your pharmaceutical business development team has ample spending and staffing resources.
Maximize Deal Position: Follow strategic recommendations to guarantee a thorough process and a well-negotiated deal. Evaluate prospective partners and see how they’ll evaluate you as you identify red flags and avoid weak deals. See who should be involved in the deal-making process and when — and learn to expertly handle the tough questions that inevitably arise.
Master Post-Deal Management: Examine real-company practices for managing partnerships, with or without a formal alliance management team. Get the right personnel involved at the right points — and build institutional memory that will protect the partnership through personnel turnover and team changes.
Excerpt from Pharmaceutical Business Development and Licensing
In recent years, R&D pipelines at large pharmaceutical companies have been hit hard due to general clinical problems, increased safety limits imposed by the FDA and changes in market access and prescribing habits. Because the pipeline is the lifeblood of any pharmaceutical company, shareholders are concerned for the health of many Top 50 companies.
On the other end of the spectrum are the smaller pharmaceutical and biotech companies. Most of these companies have been plagued by dry investor channels and limited access to public funding, even though they own clinically promising compounds and therapies with equally promising forecasted revenues. With fewer resources, they cannot afford to continue development or establish a commercial arm in preparation for product launch.